Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

OPTIMUM Study

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: OPTIMUM@thekids.org.au   What is the 

Pneumococcal Disease

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Pneumococcal disease is

News & Events

Maths, modelling and RSV: the unique combo driving virus prevention

The Kids Research Institute developed a world-first RSV transmission model using real data to predict the impact of WA’s immunisation program for young children.

2017 Update for the Vaccine Trials Group

Wrap up of the people, projects and updates from 2017 in the Vaccine Trials Group research area, and Dr Peter Richmond.

Respiratory Syncytial Virus (RSV) studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Respiratory Syncytial

Meningococcal disease

Meningococcal disease is caused by the bacteria Neisseria meningitidis, or 'meningococcus'. It's an uncommon but very serious disease that can result in death.

2021 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful recipients for the 2021 Round 2 Seed Funding Grants. Julie Hibbert | Validating a

News & Events

Major NHMRC grant prioritises strong skin for Aboriginal children

Efforts to improve health outcomes for Aboriginal children have been accelerated thanks to almost $1 million in National Health and Medical Research Council (NHMRC) funds awarded to skin health researchers at The Kids Research Institute Australia.

Research

Improving screening in a paediatric cohort for cystic fibrosis-related diabetes: A quality improvement project

André Schultz MBChB, PhD, FRACP Head, BREATH Team Head, BREATH Team Prof André Schultz is the Head, BREATH Team at The Kids Research Institute

Research

Enhanced versus standard hydration in acute ischemic stroke: REVIVE—A randomized clinical trial

Early neurological deterioration (END) within 72 h of stroke onset is associated with poor prognosis. Optimizing hydration might reduce the risk of END.